Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Kreston Reeves Audit LLP as auditor to the Company. The appointment of Kreston Reeves Audit follows a restructuring of the audit practice of Kreston Reeves LLP, the Company’s former auditor, and will be subject to approval by shareholders at the next Annual General Meeting of the Company.
Nuformix appoints Kreston Reeves Audit as new auditor
- Written by: Amilia Stone
Find more news, interviews, share price & company profile here for:
Latest Company News
Nuformix reported a reduced interim loss and a significantly improved cash position for the six months ended 31 March 2026, supported by successful fundraisings and progress with NXP002, including FDA Orphan Drug Designation in IPF.
Executive Director Dr Dan Gooding discusses Nuformix’s NXP002 programme for idiopathic pulmonary fibrosis, the value of FDA orphan drug designation, and how the recent fundraise supports partnering discussions.
Nuformix strengthens its NXP002 programme with US orphan drug designation, unlocking market exclusivity in a region accounting for the majority of IPF revenues. With fresh capital and ongoing partner discussions, the company is positioning itself to advance a differentiated inhaled therapy while negotiating from strength.
Nuformix plc has raised £1.0 million via a placing of 500 million new shares at 0.20p each. The proceeds will support additional pre-clinical studies and further development of its inhaled NXP002 treatment for pulmonary fibrosis.
The FDA has granted Orphan Drug Designation to tranilast lystate, the active compound in Nuformix’s NXP002 programme targeting idiopathic pulmonary fibrosis, a rare lung disease affecting fewer than 200,000 people in the United States.
Nuformix has received an FDA request for clarification on its Orphan Drug Designation application for tranilast under the NXP002 programme. The company also reported its Open Offer was oversubscribed by 408%, raising around £228,000 before expenses.
